Cross-sensitization between the motor activating effects of bromocriptine and caffeine: role of adenosine A(2A) receptors

Behav Brain Res. 2000 Sep;114(1-2):97-105. doi: 10.1016/s0166-4328(00)00190-x.

Abstract

The acute motor response to caffeine was studied in rats repeatedly treated with vehicle or the dopamine D(2) agonist bromocriptine either in a novel cage or in the home cage. Rats receiving bromocriptine (5 mg/kg i.p.) in a novel cage were sensitized to the motor stimulating effects of bromocriptine itself and showed cross-sensitization to the acute administration of low (10 mg/kg s.c. ) but not high (25 mg/kg s.c.) doses of caffeine, no matter if the novel cage was identical or different from the test cage. In contrast, caffeine (10 mg/kg i.p.) administered to rats which had received bromocriptine (5 mg/kg i.p.) in the home cage and which showed no sign of a sensitized response to bromocriptine, failed to show an increased locomotor and stereotyped response as compared to vehicle pretreated rats. Similarly to caffeine, the selective adenosine A(2A) antagonist SCH 58261 (3 mg/kg i.p.) showed an increased motor response in bromocriptine sensitized rats. The sensitized response to caffeine or SCH 58261 did not appear to be due to an higher basal motor activity of bromocriptine sensitized rats since acute administration of vehicle induced a similar motor response in bromocriptine and vehicle pretreated rats. Dopamine D(2) and adenosine A(2A) receptors are colocalized in striatal efferent neurons where they control in an opposite direction motor behavior. The results of the present study showed that changes in the sensitivity of D(2) receptors influenced the sensitivity of the adenosine antagonist caffeine through an action on A(2A) receptors. D(2) and A(2A) receptors, therefore, not only acutely interact in the mediation of motor behavior but long-term modification of the D(2) receptors, such as sensitization, affected the response of adenosine A(2A) receptors.

MeSH terms

  • Animals
  • Bromocriptine / pharmacology*
  • Caffeine / pharmacology*
  • Central Nervous System Stimulants / pharmacology*
  • Dopamine Agonists / pharmacology*
  • Dose-Response Relationship, Drug
  • Male
  • Motor Activity / drug effects*
  • Purinergic P1 Receptor Antagonists
  • Pyrimidines / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, Adenosine A2A
  • Receptors, Purinergic P1 / drug effects*
  • Stereotyped Behavior / drug effects
  • Stimulation, Chemical
  • Triazoles / pharmacology

Substances

  • 5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine
  • Central Nervous System Stimulants
  • Dopamine Agonists
  • Purinergic P1 Receptor Antagonists
  • Pyrimidines
  • Receptor, Adenosine A2A
  • Receptors, Purinergic P1
  • Triazoles
  • Bromocriptine
  • Caffeine